Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Penmetsa
DUAL PI3K Δ/Γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T-Cell LYMPHOMA: DOSE ESCALATION FINDINGS.
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Patients With Relapsed/Refractory T-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Phosphatidylinositol 3-Kinase-Δ (PI3K-δ) Is a Potential Therapeutic Target in Adult T-Cell Leukemia-Lymphoma
Biomarker Research
Biochemistry
Molecular Medicine
Clinical Biochemistry
Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Nelarabine Treatment in Adult Patients With Refractory/ Relapsed T-Cell Acute Lymphoblastic Leukaemia/Lymphoma: Experience of a Single Centre
Gematologiya i Transfuziologiya
Hematology
